Drug Trial Radar · NCT04262895
TTI-0102 for Veterans With TBI
Last checked: Nov 19, 2026Latest source record: Oct 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 1, 2021
Primary completion
Oct 15, 2021
Study completion Oct 15, 2021
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Feb 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Traumatic brain injury (TBI) is a signature wound of the recent wars. How chronic TBI symptoms develop after a mild brain injury is not fully understood, but it is now thought that injury results in damage that reduces brain energy production, increases inflammation, and results in a leaky blood-brain barrier. Difficulties in daily function may persist in areas such as thinking (e.g., attention, learning, memory, planning, and problem-solving), pain (e.g., headache) and behavior (e.g., sleep, posttraumatic stress disorder, depression). No medications for TBI have been developed, so evidence-based cognitive rehabilitation interventions such as Compensatory Cognitive Training (CCT) are the mainstay of treatment. The investigators are proposing to study a medication, TTI-0102, that shows anti-inflammatory activity, as a potential adjunct treatment with CCT for Veterans with TBI-related symptoms. The investigators plan to first determine the best dose of TTI-0102 to use, and then to conduct a pilot study to test the feasibility and acceptability of combining TTI-0102 with CCT in Veterans with mild to moderate TBI and PTSD.
Conditions
- Mild to Moderate TBI
- Posttraumatic Stress Disorder
Interventions
TTI-0102Drug
TTI-0102 is a cysteamine precursor.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective cognitionTime frame: Change from 0 to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VA San Diego Healthcare System, San Diego, CA
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.